What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
LaRosa
J C
JC
Tulane University Medical Center, New Orleans, Louisiana, USA.
Sneider
G B
GB
Boyle
C
C
D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation / Q000331:legislation & jurisprudence / Q000379:methods*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration
D000960:Hypolipidemic Agents; D008055:Lipids